SCHEMBL3351202

SCHEMBL3351202

Cc1csc(CN(C)C(=O)c2cccc(C(N)=O)c2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
ALDH1A1 P00352 2/20 0.42
GAA P10253 2/20 0.42
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42
GRM5 P41594 2/20 0.41
PARP1 P09874 1/20 0.40
BRD4 O60885 1/20 0.40
BRD3 Q15059 1/20 0.40
SIRT2 Q8IXJ6 1/20 0.39
ENPP2 Q13822 1/20 0.39
HSD17B1 P14061 3/20 0.38
HSD17B2 P37059 3/20 0.38
KDM4E B2RXH2 1/20 0.38
F10 P00742 1/20 0.38
GCK P35557 1/20 0.37
ADAMTS5 Q9UNA0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL168243 0.89 MEN1 (0.51) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL2711315 0.88 NPC1 (0.47) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL3648036 0.86 RAB9A (0.42) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL3508786 0.86 NPC1 (0.47) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL162235 0.86 NPC1 (0.52) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL3508802 0.85 RAB9A (0.49) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL3646471 0.85 NPC1 (0.46) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL3507433 0.85 RAB9A (0.42) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL2711948 0.84 NPC1 (0.48) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL3645339 0.84 RAB9A (0.46) NPC1RAB9AMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2178837-A2 ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY COMENTIS, INC. (US) 2010-04-28 EP claimed
WO-2009015369-A2 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2009-01-29 WO claimed
US-20100286145-A1 ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY COMENTIS, INC. (US) 2010-11-11 US disclosed
EP-2178837-A2 ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY COMENTIS, INC. (US) 2010-04-28 EP disclosed
WO-2010042030-A1 ASPARTYL PROTEASE INHIBITORS MEDIVIR AB (SE) 2010-04-15 WO disclosed
US-7504420-B2 Compounds which inhibit beta-secretase activity and methods of use COMENTIS, INC. (US) 2009-03-17 US disclosed
WO-2009015369-A2 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2009-01-29 WO disclosed
US-20080176939-A1 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2008-07-24 US disclosed
US-20070117793-A1 Compounds Which Inhibit Beta-Secretase Activity and Methods of Use ZAPAQ, INC. (US) 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117793-A1 Compounds Which Inhibit Beta-Secretase Activity and Methods of Use BACE1, BACE2, APP NPC1 281/4885RAB9A 1660/4885MEN1 3293/4885
US-20100286145-A1 ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY BACE1, BACE2, APP NPC1 204/4885RAB9A 3199/4885MEN1 3945/4885
US-20080176939-A1 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF BACE1, BACE2, APP NPC1 271/4885RAB9A 1904/4885MEN1 3308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.